Topics

Companies Related to "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)" [Most Relevant Company Matches] RSS

11:47 EDT 30th March 2020 | BioPortfolio

Here are the most relevant search results for "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)" found in our extensive corporate database of over 50,000 company records.

Showing "Targeted Treatment Fusion Positive Advanced Small Cell Lung" Companies 1–25 of 8,800+

Extremely Relevant

Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug for the treatment of advanced n...


Relevant

TP Therapeutics Inc.

TP Therapeutics is a clinical-stage precision oncology company forging a new path for targeted cancer care. Founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib, the company is developing a pipeline of novel drugs that aim to tackle treatment resistance and give new hope to patients who have ...

Turning Point Therapeutics, Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company forging a new path for targeted cancer care. Founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib, the company is developing a pipeline of novel drugs that aim to tackle treatment resistance and give new hope to patie...


Protox Therapeutics Inc.

Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drug...

OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and st...

Bristol-Myers Squibb Company 

Surgery, radiation, cytotoxic or targeted therapies have represented the mainstay of cancer treatment over the last several decades, but long-term survival and a positive quality of life have remained elusive for many patients with advanced disease.

Telik

Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small...

Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc., is a biopharmaceutical company discovering and developing Pentarins™ as a new class of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized biologic drug conjugate that targets the somatostatin receptor for treat...

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pip...

Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® ...

Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments. In preclinical studies, the Company has shown the ability to precisely target and effecti...

Neotropix, Inc.

The company has signed two key licensing agreements with strong industry partners. These agreements allow Neotropix to use novel therapeutics to conduct research and development on major cancer indications.Neotropix is preparing to begin clinical trials in 2006, and is seeking FDA approval to grant its virus orphan drug status for the treatment of small cell lung cancers. This will be the first ap...

Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. We are currently focusing our development efforts on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chem...

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and proge...

Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clin...

New Lung Associates

New Lung Associates is a pulmonary group of physicians leading the Lung Transplant Program and the Adult Cystic Fibrosis Program at Tampa General Hospital, a 988-bed acute care hospital in Tampa, Fla. The New Lung Associates team has specialized focus in the care of advanced lung diseases, cystic fibrosis, and lung transplantation. New Lung Associatesâ€...

Automated Fusion Technology Pty Ltd

Automated Fusion Technology Pty Ltd ( AFT ) was established in July 1991 as a design, manufacturing and service organisation specialising in automated fusion equipment. In addition to supplying a wide range of standard fusion machines and options, AFT provides a customised service which designs and builds equipment to meet clients' needs. The range of products includes service contracts, customise...

Advanced Cell Diagnostics, Inc.

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope(TM) technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in si...

PentixaPharm

This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma –...

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

BlinkBio Inc.

BlinkBio is a privately held, biotechnology company based in Jupiter, FL, that is advancing Tunable Drug Conjugates (TDCs), a new class of drug conjugate therapies, for the treatment of cancer and other diseases. We have designed our TDCs around our broadly enabling, proprietary SiLinker and Payload Cassette technologies. Our lead therapeutic program targe...

Practice Fusion Inc.

Practice Fusion addresses the complexities and critical needs of today's healthcare environments by providing a revolutionary free, web-based electronic health record (EHR) application and delivery model for physicians and patients. As a result, Practice Fusion is the fastest growing EHR community in the country for physicians. Practice Fusion has more than 21,000 users in 50 states. For more info...

IDEC Pharmaceuticals Corporation

IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, developmentand commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. IDEC Pharmaceuticals first commercial product, Rituxan, and their most advanced product candidate, IDEC-Y2B8, are for use in the treatment of certain B-cell NHLs. IDEC Pharmace...

VisionGate, Inc.

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. VisionGate offers the first automated 3D cell imaging platform, the Cell-CT, which computes high-resolution 3D biosignatures f...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...


More From BioPortfolio on "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)"

Quick Search

Corporate Database Quicklinks